Literature DB >> 21270130

Lef1DeltaN binds beta-catenin and increases osteoblast activity and trabecular bone mass.

Luke H Hoeppner1, Frank J Secreto, David F Razidlo, Tiffany J Whitney, Jennifer J Westendorf.   

Abstract

Lymphoid enhancer-binding factor (Lef) 1 is a high mobility group protein best known as a Wnt-responsive transcription factor that associates with β-catenin. Lef1ΔN is a short isoform of Lef1 that lacks the first 113 amino acids and a well characterized high affinity β-catenin binding domain present in the full-length protein. Both Lef1 isoforms bind DNA and regulate gene expression. We previously reported that Lef1 is expressed in proliferating osteoblasts and blocks osteocalcin expression. In contrast, Lef1ΔN is only detectable in the later stages of osteoblast differentiation and promotes osteogenesis in vitro. Here, we show that Lef1ΔN retains the ability to interact physically and functionally with β-catenin. Unlike what has been reported in T cells and colon cancer cell lines, Lef1ΔN activated gene transcription in the absence of exogenous β-catenin and cooperated with constitutively active β-catenin to stimulate gene transcription in mesenchymal and osteoblastic cells. Residues at the N terminus of Lef1ΔN were required for β-catenin binding and the expression of osteoblast differentiation genes. To determine the role of Lef1ΔN on bone formation in vivo, a Lef1ΔN transgene was expressed in committed osteoblasts using the 2.3-kb fragment of the type 1 collagen promoter. The Lef1ΔN transgenic mice had higher trabecular bone volume in the proximal tibias and L5 vertebrae. Histological analyses of tibial sections revealed no differences in osteoblast, osteoid, or osteoclast surface areas. However, bone formation and mineral apposition rates as well as osteocalcin levels were increased in Lef1ΔN transgenic mice. Together, our data indicate that Lef1ΔN binds β-catenin, stimulates Lef/Tcf reporter activity, and promotes terminal osteoblast differentiation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21270130      PMCID: PMC3064150          DOI: 10.1074/jbc.M110.165100

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Dominance of SOX9 function over RUNX2 during skeletogenesis.

Authors:  Guang Zhou; Qiping Zheng; Feyza Engin; Elda Munivez; Yuqing Chen; Eiman Sebald; Deborah Krakow; Brendan Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-01       Impact factor: 11.205

Review 2.  Wnt signalling: variety at the core.

Authors:  Stefan Hoppler; Claire Louise Kavanagh
Journal:  J Cell Sci       Date:  2007-02-01       Impact factor: 5.285

3.  Wnt activation and alternative promoter repression of LEF1 in colon cancer.

Authors:  Tony W-H Li; Ju-Hui T Ting; Noriko N Yokoyama; Alla Bernstein; Marc van de Wetering; Marian L Waterman
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

4.  LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia.

Authors:  Julia Skokowa; Gunnar Cario; Murat Uenalan; Axel Schambach; Manuela Germeshausen; Karin Battmer; Cornelia Zeidler; Ulrich Lehmann; Matthias Eder; Christopher Baum; Rudolf Grosschedl; Martin Stanulla; Michaela Scherr; Karl Welte
Journal:  Nat Med       Date:  2006-09-24       Impact factor: 53.440

5.  Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT.

Authors:  Maria Almeida; Li Han; Teresita Bellido; Stavros C Manolagas; Stavroula Kousteni
Journal:  J Biol Chem       Date:  2005-10-25       Impact factor: 5.157

Review 6.  Diversity of LEF/TCF action in development and disease.

Authors:  L Arce; N N Yokoyama; M L Waterman
Journal:  Oncogene       Date:  2006-12-04       Impact factor: 9.867

7.  Human sebaceous tumors harbor inactivating mutations in LEF1.

Authors:  Hikaru Takeda; Stephen Lyle; Alexander J F Lazar; Christos C Zouboulis; Ian Smyth; Fiona M Watt
Journal:  Nat Med       Date:  2006-03-26       Impact factor: 53.440

8.  Essential role of beta-catenin in postnatal bone acquisition.

Authors:  Sheri L Holmen; Cassandra R Zylstra; Aditi Mukherjee; Robert E Sigler; Marie-Claude Faugere; Mary L Bouxsein; Lianfu Deng; Thomas L Clemens; Bart O Williams
Journal:  J Biol Chem       Date:  2005-03-31       Impact factor: 5.157

9.  Lymphocyte enhancer-binding factor 1 (Lef1) inhibits terminal differentiation of osteoblasts.

Authors:  Rachel A Kahler; Mario Galindo; Jane Lian; Gary S Stein; Andre J van Wijnen; Jennifer J Westendorf
Journal:  J Cell Biochem       Date:  2006-04-01       Impact factor: 4.429

10.  Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context.

Authors:  Amanda J Mikels; Roel Nusse
Journal:  PLoS Biol       Date:  2006-04-04       Impact factor: 8.029

View more
  17 in total

Review 1.  Cell-context dependent TCF/LEF expression and function: alternative tales of repression, de-repression and activation potentials.

Authors:  Catherine D Mao; Stephen W Byers
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2011       Impact factor: 1.807

Review 2.  Update on Wnt signaling in bone cell biology and bone disease.

Authors:  David G Monroe; Meghan E McGee-Lawrence; Merry Jo Oursler; Jennifer J Westendorf
Journal:  Gene       Date:  2011-11-03       Impact factor: 3.688

Review 3.  A Comprehensive Overview of Skeletal Phenotypes Associated with Alterations in Wnt/β-catenin Signaling in Humans and Mice.

Authors:  Kevin A Maupin; Casey J Droscha; Bart O Williams
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

4.  Physical activity and hypocaloric diet recovers osteoblasts homeostasis in women affected by abdominal obesity.

Authors:  Viviana M Bimonte; Simona Fittipaldi; Chiara Marocco; Gian Pietro Emerenziani; Rachele Fornari; Laura Guidetti; Eleonora Poggiogalle; Emanuele Nicolai; Luigi Di Luigi; Lorenzo M Donini; Carlo Baldari; Andrea Lenzi; Emanuela A Greco; Silvia Migliaccio
Journal:  Endocrine       Date:  2016-12-16       Impact factor: 3.633

Review 5.  WNT signaling in bone homeostasis and disease: from human mutations to treatments.

Authors:  Roland Baron; Michaela Kneissel
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

6.  miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells.

Authors:  Mohammad Q Hassan; Yukiko Maeda; Hanna Taipaleenmaki; Weibing Zhang; Mohammad Jafferji; Jonathan A R Gordon; Zhaoyong Li; Carlo M Croce; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

Review 7.  Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment.

Authors:  Larion Santiago; Garrett Daniels; Dongwen Wang; Fang-Ming Deng; Peng Lee
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

Review 8.  Wnt and the Wnt signaling pathway in bone development and disease.

Authors:  Yiping Wang; Yi-Ping Li; Christie Paulson; Jian-Zhong Shao; Xiaoling Zhang; Mengrui Wu; Wei Chen
Journal:  Front Biosci (Landmark Ed)       Date:  2014-01-01

9.  Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice.

Authors:  Xiaofang Wang; Suzhen Wang; Changcheng Li; Tian Gao; Ying Liu; Afsaneh Rangiani; Yao Sun; Jianjun Hao; Anne George; Yongbo Lu; Jay Groppe; Baozhi Yuan; Jian Q Feng; Chunlin Qin
Journal:  PLoS Genet       Date:  2012-05-17       Impact factor: 5.917

10.  Stromal β-catenin activation impacts nephron progenitor differentiation in the developing kidney and may contribute to Wilms tumor.

Authors:  Keri A Drake; Christopher P Chaney; Amrita Das; Priti Roy; Callie S Kwartler; Dinesh Rakheja; Thomas J Carroll
Journal:  Development       Date:  2020-07-31       Impact factor: 6.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.